Johnson & Johnson is a famous American multinational company established in 1886. It focuses on medical devices, pharmaceuticals, and consumer health products. Based in New Brunswick, New Jersey, the company operates in over 60 countries worldwide. Its products are distributed globally, making them widely accessible.
Johnson & Johnson is known for its commitment to improving health and well-being, offering a broad range of trusted products, from baby care items like Johnson’s Baby, to life-saving medications and advanced medical technologies. With a strong focus on innovation, research, and development, the company continues to lead in various healthcare sectors, enhancing the quality of life for millions of people worldwide.
Johnson & Johnson Fiscal Q1 2025
Johnson & Johnson (JNJ) had a strong Q1 2025, with both earnings and revenue exceeding expectations. Sales grew by 2.4% to $21.9 billion, driven by operational growth of 4.2% and adjusted growth of 3.3%.
Also, EPS increased to $4.54, boosted by special charge reversals, while adjusted EPS rose by 2.2% to $2.77.
The company made key progress in its pipeline, including the approval of TREMFYA for Crohn’s disease, positive results for RYBREVANT and LAZCLUZE in lung cancer, advancements in icotrokinra for psoriasis, and clinical trials for its OTTAVA robotic system.
Johnson & Johnson also raised its full-year sales guidance, reflecting the CAPLYTA acquisition, and maintained its EPS growth outlook of 6.2% despite challenges like tariffs and foreign exchange impacts.
2025 Guidance
- Sales Growth: Sales are expected to grow between 2% and 3%. Total sales could reach $91.6 to $92.4 billion, depending on the year’s performance.
- Earnings Per Share (EPS): Adjusted EPS is predicted to be $10.50 to $10.70, a growth of about 5% to 7%.
This guidance shows steady growth, despite uncertainties that could affect some results.
Board Statements
Joaquin Duato, Chairman and CEO of Johnson & Johnson, highlighted the company’s strong operational sales growth this quarter as a reflection of the power of its diversified portfolio and reaffirmed confidence in its 2025 guidance.
He also emphasized Johnson & Johnson’s advancements as an innovation leader, noting progress in its pipeline with TREMFYA for inflammatory bowel disease (IBD), RYBREVANT combined with LAZCLUZE for non-small-cell lung cancer, and the OTTAVA soft tissue surgical robotic system.
Additionally, Duato mentioned the enhancement of the company’s neuroscience portfolio through the acquisition of Intra-Cellular Therapies.
Impact on the Market
Johnson & Johnson’s Q1 2025 earnings had a mixed effect on its stock. While revenue and EPS beat expectations, the stock dropped 1%. This could be due to concerns about tariffs, foreign exchange impacts, and costs from its recent acquisition. Despite the dip, the strong results and raised sales guidance show the company’s solid performance and growth potential.
